Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04430179 · ClinicalTrials.gov registry record · Phase 2
Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
A Phase 2 study of Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis, sponsored by University of South Florida.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04430179: Active Phase 2 study of Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis, sponsored by University of South Florida.
NCT04430179 is a Phase 2 study of Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis that is active but no longer recruiting, run by University of South Florida. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04430179, a Phase 2 study of Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis, is active but no longer recruiting, sponsored by University of South Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will investigate the efficacy of dupilumab in patients with severe eosinophilic CRSsNP who are resistant to the conventional treatment with intranasal corticosteroids and have significantly extensive disease involving more than 2 sinuses bilaterally in sinus CT scan and Lund-Mackay sinus (LMK) CT score \>=10 at baseline.
Primary Outcome
Change in LMK-CT score in dupilumab group compared to control group. The total score ranges from 0 (normal) - 24 (more opacified): higher score indicates worse status.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Study Locations (1)
Florida
- University of South Florida Asthma, Allergy and Immunology - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-12-17 |
| Est. Completion | 2025-07 |
| Phase | Phase 2 |
What the registry record for NCT04430179 still lists
NCT04430179 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04430179 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04430179 about?
NCT04430179 is a clinical study titled "Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis". The investigators will investigate the efficacy of dupilumab in patients with severe eosinophilic CRSsNP who are resistant to the conventional treatment with intranasal corticosteroids and have significantly extensive disease involving more than 2 sinuses bilaterally in sinus CT scan and Lund-Mackay...
What is the current status of trial NCT04430179?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2020-12-17. Estimated completion is 2025-07.
What conditions does trial NCT04430179 study?
This clinical trial studies the following conditions: Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis.
What interventions are being tested in trial NCT04430179?
The interventions under investigation include: Placebo (OTHER), Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] (DRUG).
Who is sponsoring clinical trial NCT04430179?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04430179 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04430179's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI